Drug Profile
Research programme: heat shock protein-viral antigen fusions - Akela Pharma
Alternative Names: Hsp 6/11Latest Information Update: 18 Mar 2013
Price :
$50
*
At a glance
- Originator Nventa Biopharmaceuticals Corporation
- Developer Akela Pharma
- Class Antigens; Heat shock proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis B; Hepatitis C; Herpes simplex virus infections; HIV infections; Human papillomavirus infections